Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Finland.
Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.
Nucleic Acids Res. 2023 Jul 5;51(W1):W57-W61. doi: 10.1093/nar/gkad390.
Functional precision medicine (fPM) offers an exciting, simplified approach to finding the right applications for existing molecules and enhancing therapeutic potential. Integrative and robust tools ensuring high accuracy and reliability of the results are critical. In response to this need, we previously developed Breeze, a drug screening data analysis pipeline, designed to facilitate quality control, dose-response curve fitting, and data visualization in a user-friendly manner. Here, we describe the latest version of Breeze (release 2.0), which implements an array of advanced data exploration capabilities, providing users with comprehensive post-analysis and interactive visualization options that are essential for minimizing false positive/negative outcomes and ensuring accurate interpretation of drug sensitivity and resistance data. The Breeze 2.0 web-tool also enables integrative analysis and cross-comparison of user-uploaded data with publicly available drug response datasets. The updated version incorporates new drug quantification metrics, supports analysis of both multi-dose and single-dose drug screening data and introduces a redesigned, intuitive user interface. With these enhancements, Breeze 2.0 is anticipated to substantially broaden its potential applications in diverse domains of fPM.
功能精准医学(fPM)提供了一种令人兴奋的、简化的方法,可用于寻找现有分子的合适应用,并增强治疗潜力。确保结果高度准确和可靠的综合和强大工具至关重要。为了满足这一需求,我们之前开发了 Breeze,这是一个药物筛选数据分析管道,旨在以用户友好的方式促进质量控制、剂量反应曲线拟合和数据可视化。在这里,我们描述了 Breeze 的最新版本(版本 2.0),它实现了一系列先进的数据探索功能,为用户提供了全面的后期分析和交互式可视化选项,这对于最小化假阳性/阴性结果并确保药物敏感性和耐药性数据的准确解释至关重要。Breeze 2.0 网络工具还支持将用户上传的数据与公开可用的药物反应数据集进行集成分析和交叉比较。更新后的版本还纳入了新的药物定量指标,支持多剂量和单剂量药物筛选数据的分析,并引入了重新设计的直观用户界面。通过这些增强功能,Breeze 2.0 有望在功能精准医学的各个领域中大大拓宽其潜在应用。